Revvity beats Q3 expectations and raises 2026 guidance
Revvity reported third-quarter 2026 revenue of $729 million on November 3, 2026, while pro forma revenue excluding the China Immunodiagnostics business reached $710 million, up 7% year over year. The company raised its 2026 outlook to approximately $2.86 billion in revenue and adjusted EPS of $5.40-$5.45. Management attributed the performance to broad-based growth and strong execution.
Why it matters
The raised outlook gives investors a higher company forecast for 2026 revenue and adjusted earnings. Pro forma results exclude the China Immunodiagnostics business pending divestiture, separating continuing operations from the reported totals.
Key facts
- 1Revvity reported third-quarter revenue of $729 million, up 4% year over year. finance.yahoo.com
- 2Third-quarter pro forma revenue excluding the China Immunodiagnostics business was $710 million, with pro forma organic revenue also increasing 7%. finance.yahoo.com
- 3Life Sciences revenue was $380 million, with pro forma growth of 11% and pro forma organic growth of 9%. finance.yahoo.com
- 4Revvity forecast 2026 revenue of $2.86B and adjusted EPS of $5.40-$5.45. investing.com
- 5Revvity scheduled its 2026 Investor Day for November 13, 2026. stocktitan.net
Open questions
- The materials give conflicting Q3 adjusted EPS figures of $1.37 and $1.38 without consistently stating whether they use the same basis.
Summary written by AlphAI AI Desk from 15 of 15 sources. Not investment advice. Figures are as stated by the linked sources.